



Pathology & Immunology Genomic & Molecular Pathology

Author: Lulu Sun, MD; Cynthia Ma, MD; Fouad Boulos, MD

Purpose: To document the expectations of algorithmic test selection and approval for diagnosis-specific solid tumor testing by the Pathologists at Washington University School of Medicine.

Workflow: All orders submitted for surgical pathology on inpatient and outpatient solid tumors are assessed for the appropriateness of testing based on correlation with new and existing clinical data. The approval process only applies to solid tumors and only to the specific testing detailed within this document. The Pathologist reviewing the surgical pathology case will be responsible for the triaging of orders.

- Requests for algorithmic testing require that the surgical pathology be resulted prior to ordering of any assays listed in this document. In cases where sample processing would be delayed beyond stability requirements, testing will be sent but may be canceled if later deemed inappropriate based on clinicopathologic data.
- If specific testing is required outside of the algorithmic test selection, please submit a separate order and the Pathologist will evaluate for approval.

Summary of diagnosis-specific algorithm testing for both inpatients and outpatients:

- I. Breast Cancer
 - a. Metastatic Breast Cancer, not including to sentinel lymph nodes.
 - i. ER/PR/HER2 IHC with reflex to HER2 FISH on equivocal 2+ cases.
 - ii. PD-L1 22c3 IHC
 - iii. GatewaySeq with Interpretation